C.M. Bidwell & Associates’s Relay Therapeutics RLAY Stock Holding History

C.M. Bidwell & Associates’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-543	Closed	-$3.84K	–	530
2024 Q3	$3.84K	Buy	543 +147	+37%	+$1.1K	﹤0.01%	385
2024 Q2	$2.58K	Hold	396	–	–	﹤0.01%	401
2024 Q1	$3.29K	Hold	396	–	–	﹤0.01%	382
2023 Q4	$4.36K	Buy	+396	New	+$3.34K	﹤0.01%	338
2023 Q2	–	Sell	-65	Closed	-$1.07K	–	573
2023 Q1	$1.07K	Buy	+65	New	+$1.17K	﹤0.01%	493

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

C.M. Bidwell & Associates's RLAY Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 543 shares — an estimated $3.84K sold.

C.M. Bidwell & Associates first reported a position in RLAY in Q1 2023 and held it in 5 quarters. The position peaked at $4.36K in Q4 2023. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

C.M. Bidwell & Associates reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
C.M. Bidwell & Associates sold 543 Relay Therapeutics shares in Q4 2024, an estimated $3.84K.
C.M. Bidwell & Associates first reported a position in Relay Therapeutics in Q1 2023 and held it in 5 quarters.
C.M. Bidwell & Associates's Relay Therapeutics position peaked at $4.36K in Q4 2023.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.